IP Library › Granted Patent US 10,982,212
Granted Patent B2
US 10,982,212 · App. 15/965,309 · Granted Apr 20, 2021

Conserved HBV and HCV sequences useful for gene silencing

Inventors: Catherine J Pachuk (Cambridge, MA); Chandrasekhar Satishchandran (Cambridge, MA); Vincent R. Zurawski (Cambridge, MA); Liat Mintz (Cambridge, MA)
Assignee: ALNYLAM PHARMACEUTICALS, INC.
C12N15/1131A61K31/713C12N2310/14C12N2310/531C12N2320/30C12N2320/32C12N2730/10122C12N2770/24222
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,212
App. No.
15/965,309
Granted
Apr 20, 2021
Kind
B2
Abstract

Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.

Claims (10)

1. A composition for inhibiting the expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising a double-stranded RNA effector molecule, wherein the double-stranded RNA effector molecule comprises (a) SEQ ID NO: 52 and the reverse complement of SEQ ID NO: 52, wherein U is substituted for T; or (b) SEQ ID NO: 53 and the reverse complement of SEQ ID NO: 53, wherein U is substituted for T.

2. The composition of claim 1 , wherein the double-stranded effector molecule comprises SEQ ID NO: 52 and the reverse complement of SEQ ID NO: 52, wherein U is substituted for T.

3. The composition of claim 1 , wherein the double-stranded effector molecules comprises SEQ ID NO: 53 and the reverse complement of SEQ ID NO: 53, wherein U is substituted for T.

4. The composition of claim 1 , wherein the double-stranded RNA effector molecule comprises SEQ ID NO: 16, wherein U is substituted for T.

5. The composition of claim 1 , wherein the double-stranded RNA effector molecule comprises SEQ ID NO: 17, wherein U is substituted for T.

6. A method for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising administering to said cell the double-stranded RNA effector molecule of claim 1 .

7. The method of claim 6 , wherein the double-stranded effector molecule comprises SEQ ID NO: 52 and the reverse complement of SEQ ID NO: 52, wherein U is substituted for T.

8. The method of claim 6 , wherein the double stranded effector molecule comprises SEQ ID NO: 53 and the reverse complement of SEQ ID NO: 53, wherein U is substituted for T.

9. The method of claim 6 , wherein the double-stranded RNA effector molecule comprises SEQ ID NO: 16, wherein U is substituted for T.

10. The method of claim 6 , wherein the double-stranded RNA effector molecule comprises SEQ ID NO: 17, wherein U is substituted for T.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: PACHUK, CATHERINE J.; SATISHCHANDRAN, CHANDRASEKHAR; ZURAWSKI, VINCENT R., JR.; MINTZ, LIAT
To: NUCLEONICS, INC.
Reel/Frame 052552/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: NUCLEONICS, INC.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 052552/0768 →
Continuity (7)
Continuation 14921510 · Oct 23, 2015
Continuation 14043272 · Oct 1, 2013
Continuation 13065601 · Dec 12, 2005
Continuation In Part PCTUS2004019229 · Jun 10, 2004
Provisional Application 60478076 · Jun 12, 2003
Provisional Application 60638294 · Dec 22, 2004
Related Publication 20190100757A1 · Apr 4, 2019